Forte Biosciences, Inc.

NASDAQ:FBRX

Biotechnology

Healthcare
$76.99 +1.71%

+$0.30 today

Market cap
$1.58B
Beta
2.87
P/E (TTM)
-42.1
EPS (TTM)
-$0.43
52W Low $9.10High $35.80

Volume 0.00M

Average 0.30M

FBRX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Forte Biosciences, Inc.NASDAQ: FBRX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $22.14M (cash outflow) rose 41.4% year over year, behind the +73.5% change in trailing-twelve-month net income. Sequentially, it fell 10.7% from the prior quarter. Over 3 fiscal years it compounded at +71.0% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$604.31M (+771.1%) for the fiscal year ending Dec 2026, a step up from the +95.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.14M-10.7% QoQ
Last fiscal yearDec 2025
-$69.38M+95.5% YoY
LTMMar 2026
-$75.86M+73.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.4%+1533.3%+1491.9 pp
1 year+95.5%+771.1%+675.5 pp
3-year CAGR+71.0%+103.6%+32.6 pp
5-year CAGR+65.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(69.38M) USD
Year-over-year change
-95.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How FBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +73.5% is the highest of 10, against a peer median of -10.2%.
  • Over three fiscal years its annual growth of +71.0% compares with a peer median of +4.6%.
FBRX Competitors
Net Income for FBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$129.91M USD-26.1%-21.5%2056.8%
ALECAlector, Inc.LTM Mar 2026$125.39M USD+1.6%+2.3%680.8%
NKTXNkarta, Inc.LTM Mar 2026$99.93M USD-10.2%-2.9%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$84.53M USD+68.1%+22.9%—
PEPGPepGen Inc.LTM Mar 2026$77.22M USD-24.4%+9.1%—
FBRXForte Biosciences, Inc.LTM Mar 2026$75.86M USD+73.5%+71.0%—
MOLNMolecular Partners AGLTM Mar 2026CHF 64.16M CHF+7.8%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$44.76M USD-8.4%+5.8%8526.1%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$40.19M USD-21.6%+11.9%—
ACTUActuate Therapeutics IncLTM Mar 2026$21.54M USD-14.9%+3.3%—
Peer median (excluding FBRX) —-10.2%+4.6%2056.8%

Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.71M)(13.88M)(31.48M)(35.48M)(69.38M)
Depreciation & Amortization36K09K39K64K
Deferred Income Tax00001.04M
Stock-Based Compensation4.21M4.02M3.28M3.1M6.26M
Change in Working Capital720K1.68M(392K)1.76M11.37M
Accounts Receivables00000
Inventory00000
Accounts Payables(294K)207K271K3.02M5.54M
Other Working Capital1.01M1.47M(663K)(1.26M)5.83M
Other Non-Cash Items61K0(131K)(158K)(237K)
Operating Cash Flow(16.68M)(8.19M)(28.71M)(30.75M)(50.88M)
Capital Expenditures00(88K)(37K)(116K)
Acquisitions (Net)00000
Purchases of Investments00(9.97M)(35.96M)0
Sales of Investments0010.1M036.35M
Other Investing Activities00000
Investing Cash Flow0047K(35.99M)36.23M
Debt Repayment00000
Common Stock Issued62K7.23M24.74M53M76.83M
Common Stock Repurchased000(1K)0
Dividends Paid00000
Other Financing Activities(106K)12K(44K)(1.14M)(7.47M)
Financing Cash Flow(44K)7.24M24.68M51.86M69.36M
Effect of Forex Changes00000
Net Change in Cash(16.72M)(944K)(3.98M)(14.88M)54.71M
Free Cash Flow(16.68M)(8.19M)(28.79M)(30.78M)(51M)

Forte Biosciences, Inc.

NASDAQ:FBRX

Intrinsic Alpha fair value

Locked

Current Price

$76.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.